Search Results

By HAGOP M. KANTARJIAN, MD, FASCO; SHILPA PAUL, PharmD, BCOP; AND FADI G. HADDAD, MD  / June 10, 2025

Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy

With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...